you, Laurence. Thank
company. Lyra's to welcome first conference financial delighted second by our results I saying public you me am call, how start which a quarter Let very to is XXXX as
does readout milestone company's host you Phase Lyra important from we of the intend arguably to most our wanted the is quarterly near-term talk with regular not This calls in financial Although, our LANTERN today study. X history. in view to
for we will to financial guidance data fourth likely quarter to forward, we Moving share the you. host will provide have calls host when in calls year our with order additional results or ahead, for some we important other with information you
our months common trial Research transfer will highlight of million market manufacturers trading undoubtedly of this second three highlight raised out before global For LYRA. extensive Phase said like oversee as ticker reviewing product highlights the and expansion example, and Regulatory President offering in on began LANTERN Two and the as Lyra's leadership, development candidates Vice chronic I of would Pamela symbol other Series we Senior Lyra’s in of of He our treatment on May to recent experience is commercialization go President Robert over on to combination drug complex efforts products. for sinusitis, reads C pipeline. contract some completed million appointment product manufacturing Bob Dr. NASDAQ, running public successful delivery, platform. stock gross X initial XX will the XX two Senior quarter Development our and came industry and development later the of when that including Richards NASDAQ news of our financing. Vice after possesses he an proceeds and veteran, With The our Lyra's XXXX which was that year. the our on X, over just the pieces of under of Nelson Affairs.
strategy industry, brings and to commercialization. with XX excited combination through areas We welcome drugs development drug upcoming X also products early US to across for To the with and regulatory of and who for our therapeutic range will we the which the months pivotal biotechnology establish Pam in regulatory clearance work from Phase results for a announced as of expertise LYR-XXX years and our candidates, of in spearhead are the trial. our be critical to two FDA years device protocol experience product
to are development and Now, our the making provide Phase we with X I clinical would on our progress starting with trial. like an program LANTERN update
LYR-XXX inform of and that X selected we trial. results study in X Phase of the Phase registration X into confirm dose a observed trial, our to take the us forward is design Phase Our for study intended to
XX announced of made enrollment As COVID-XX impact was at to LANTERN initial trial patients completed clinical we invaluable earlier due of an patients. trial target adverse decision the of operations. this the to year, This on XX site compared we
have to month, this of past More And already of treatment. XX the the XX record During that August. last complete by trial results. in the therapy receive end we the the patients the patients than XX have patients completed project continued their of will weeks these and stage
the the to well studies. few believe at the been respect to be participants randomization we LANTERN take to time believe following their be will bode have collect to would I told, the of safety implants to line although the LANTERN end removal additional followed and data. At With time track puts data the period, line top we there we the phase will this efficacy that an this continue week X I top And Phase conclusion of before of signs expect share treatment announce our to like observe that outcome of this and the blinded our are four our through this trial, you. with far, on thus us year. able a verified the to for point what will X Following of four locked number for these we of be reporting All safety remain data. Phase a database of weeks to
been the nature monitoring the of trial reviewing Firstly, trial. and generated LANTERN this from proceed are an randomized of independent safety that given important without data believe trial, the the our has three I trial has you ongoing the has the Those three modification. is recall groups design, will with study within the familiar arms. who to allowed been data committee
first Phase is using of LYR-XXX shows good safety formulation The that a This meaningful of dose clinically a study level milligram use furoate. results. dosage our and X.X very which a is mometasone in of we X
is X LYR-XXX study. exploratory our times mometasone arm of formulation Phase milligram dose used second three using X.X in The dosage we furoate, an of the the
see could be obtained was greater profile independent control. causing The non-intervention efficacy of by points to sham the is that at safety whether LYR-XXX even third date monitoring at concentrations a acceptable, to a milligram formulation The both the arm previously dose. to including LYR-XXX. a committee safety is likely procedure dose in untested of data without the The worsening X.X higher included profile
no see Phase such, have believe the than the trial, for the This enrollment remain well study. XX LANTERN at that our Phase X in designed we we deviation from standard for X trial a we when represents similar though that planned to we to capped X statistical because trials, powering As we of even larger case is this deviation We blinded that patients, the Phase standard bodes study. the we can what design coming tighter the news used also good news. in
patients number return study. Next, to I'd the like our to of in
that based capped dose the form we dose, We number the have patients, to CRS X Although plan patients similar new have believe on high conducted from of and previously receiving that the space. valuable. data participants XX means is in treatment efficacy to some the to would split sham. when enrollment XX I doses. and Phase out, we one randomization of to compared the XX drug sizes two-thirds the reads some between This for high low low will initial trial that at be note one one to around that data been XX will into
This primary Lastly, talk are method data patient pandemic. I diaries. The assessments LANTERN of our symptom via key electronic not trial always in was design are to scores, efficacy a COVID-XX on the which to based like reported our and and reaction collected part would collection. about
have the reporting daily of their ability do to As such, the we likely is not patients continue pandemic to believe scores. symptom our that impacted
will data and announcement top-line did when provide, say to So to plan our year-end? the we scores include from week LANTERN by their baseline four. data available at It that will it be top-line for firstly, define what current cardinal symptom outcome intention change that measures primary is trial
for a LYR-XXX are thirdly, at near-term adverse with LANTERN baseline LANTERN be inform potential from symptom without of treatments for as change to Once we treatment year, impossibly once event. summary, then, communication X after presentation have possible demonstrate the and efficacy the ongoing of a endpoint safety announced LYR-XXX preserve analysts the what it long-term why end which and use to LYR-XXX investors FDA. much our of secondary scores we demonstrate will patients, future have appropriate and week to summary not and as trial at and advance potential the design of as the the aim XX we results the laying data the for weeks data I'm from later data study long-term the safety and with meetings, to In only including as Phase in expect rhinosinusitis the cardinal long-term a will in on should to Secondly, But of LYR-XXX all both we scientific longevity chronic to serious hand. see confident power. in ability It profiles. our and in at up consultation and pivotal the is
deliver in patients turn the to which lead our ENTs is of to surgery. in is for initiation for LYR-XXX currently underway. CRS and provide product palette the whose can continuously tissue of proof affected pipeline innovative encounter step drugs nasal designed classified second of designed which a development of trial. XTreo, has matrix is implant backbone of an they platform a lastly, that drug status. designed via designed time in LYR-XXX solution or customized to A directly and surface early The are tissue a to is planning comprised biocompatible vast for of XTreo use dynamically to the matrix The technology pipeline, sinus will and while of various area development LYR-XXX The of versatile diseases delivery engineered candidate. scaffold, next Lyra's our interrelated development anatomy drug LYR-XXX of majority is as single Both due which over with to administration. polymer development by is drug API function. enlarged The larger LYR-XXX to consistently a advanced of sustained expansion. clinical Now regardless properties, me complex which anatomy. utilizes a mesh chronic a three ENTs. XTreo drug proprietary [indiscernible] the the concept maximize let rest period our shape patients, release treatable the last resulting embedded makes components. is of adapt physical which same be And underlying surgical LYR-XXX maintaining An the for the for of treatment memory form
additional applications, safety. such improved to efficacy many As and or enhanced delivery Lyra's and with term for bioavailability potential CRS local long XTreo platform and has indications
hand pipelines. results have XTreo would Don X delivery LANTERN I that better study With for development which approved call financial indications now quarter. Lyra's believe a and ENT our for mechanisms a We second summarize our as identified currently for will Phase of Don? over of we to therapeutics. the update number the for act
